CARENEXA LLC NPI 1790021517

NPI Details

CARENEXA, LLC is a clinical medical laboratory in Vancouver, WA. The provider is (1) A clinical laboratory is a facility for the biological, microbiological, serological, chemical, immunohematological, hematological, biophysical, cytological, pathological, or other examination of materials derived from the human body for the purpose of providing information for the diagnosis, prevention, or treatment of any disease or impairment of, human beings. These examinations also include procedures to determine, measure, or otherwise describe the presence or absence of various substances or organisms in the body. Facilities only collecting or preparing specimens (or both) or only serving as a mailing service and not performing testing are not considered clinical laboratories. (2) Any facility that examines materials from the human body for purposes of providing information for the diagnosis, prevention, or treatment of any disease or impairment of, or the assessment of, the health of human beings. Typical divisions of a clinical laboratory include hematology, cytology, bacteriology, histology, biochemistry, medical toxicology, and serology. CARENEXA, LLC NPI is 1790021517. The provider is registered as an organization entity type.
The provider Is Doing Business As Molecular Testing Labs.

The provider's business location address is:

14401 SE 1ST ST
VANCOUVER, WA
ZIP 98684-503
Phone: (855) 685-5227

The provider's authorized official is Rene Nicole Hurst-wall .
The authorized official title is Senior Manager Payor Relations and has the following contact phone number (360) 208-0758.

The CLIA number assigned to this NPI record is 50D2050397 - independent with a certificate type of Certificate of Accreditation.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Detection test by nucleic acid for organism, amplified probe technique (HCPCS:87798)
• Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r (HCPCS:U0003)
• Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within (HCPCS:U0005)
• Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (HCPCS:G0481)
• Testing for presence of drug, by chemistry analyzers (HCPCS:80307)
• Detection test by nucleic acid for strep (streptococcus, group b), amplified probe technique (HCPCS:87653)
• Detection test for candida species (yeast), amplified probe technique (HCPCS:87481)
• Detection test by nucleic acid for staphylococcus aureus (bacteria), amplified probe technique (HCPCS:87640)
• Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (HCPCS:G0480)
• Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (HCPCS:G0482)
• Detection test by nucleic acid for neisseria gonorrhoeae (gonorrhoeae bacteria), amplified probe technique (HCPCS:87591)
• Detection test by nucleic acid for chlamydia trachomatis, amplified probe technique (HCPCS:87491)
• Detection test by nucleic acid for vancomycin resistance strep (vre), amplified probe technique (HCPCS:87500)
• Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (HCPCS:G0483)
• Analysis for antibody, treponema pallidum (HCPCS:86780)
• Detection test by immunoassay technique for hiv-1 antigen and hiv-1 and hiv-2 antibodies (HCPCS:87389)
• Blood creatinine level (HCPCS:82565)
• Hepatitis c antibody measurement (HCPCS:86803)
• Detection test by immunoassay technique for hepatitis b surface antigen (HCPCS:87340)
• Detection test by nucleic acid for staphylococcus aureus, methicillin resistant (mrsa bacteria), amplified probe technique (HCPCS:87641)

The enumeration date for this NPI number is 12/26/2012 and was last updated on 11/8/2024.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: